DXCM | DexCom, Inc.

IndexNDX, S&P 500 P/E180.20 EPS (ttm)0.69 Insider Own0.10% Shs Outstand386.70M Perf Week1.44%
Market Cap47.02B Forward P/E83.06 EPS next Y1.50 Insider Trans-40.32% Shs Float384.65M Perf Month1.44%
Income292.50M PEG9.39 EPS next Q0.23 Inst Own98.80% Short Float / Ratio3.76% / 6.37 Perf Quarter15.38%
Sales3.02B P/S15.56 EPS this Y57.80% Inst Trans-0.36% Short Interest14.46M Perf Half Y5.45%
Book/sh5.77 P/B21.55 EPS next Y37.47% ROA5.60% Target Price140.70 Perf Year62.59%
Cash/sh6.79 P/C18.32 EPS next 5Y19.20% ROE13.90% 52W Range67.11 - 126.59 Perf YTD9.80%
Dividend- P/FCF113.04 EPS past 5Y37.80% ROI8.20% 52W High-1.78% Beta1.15
Dividend %- Quick Ratio1.80 Sales past 5Y32.30% Gross Margin64.90% 52W Low85.28% ATR3.71
Employees7500 Current Ratio2.00 Sales Q/Q17.90% Oper. Margin13.10% RSI (14)58.63 Volatility3.69% 3.07%
OptionableYes Debt/Eq0.91 EPS Q/Q-48.80% Profit Margin9.70% Rel Volume0.93 Prev Close121.13
ShortableYes LT Debt/Eq0.56 EarningsApr 27 AMC Payout0.00% Avg Volume2.27M Price124.34
Recom1.50 SMA204.45% SMA504.74% SMA20013.86% Volume2,121,056 Change2.65%
Date Action Analyst Rating Change Price Target Change
May-30-23Resumed Morgan Stanley Equal-Weight $131
Apr-17-23Upgrade Raymond James Outperform → Strong Buy $127 → $138
Mar-29-23Initiated UBS Buy $142
Jan-26-23Initiated Wolfe Research Outperform $121
Oct-18-22Initiated Barclays Equal Weight $103
Oct-12-22Initiated Jefferies Buy $125
Jul-15-22Initiated Bernstein Outperform $105
Mar-02-22Resumed BofA Securities Buy $500
Feb-03-22Upgrade BTIG Research Neutral → Buy $535
Jan-19-22Upgrade Wells Fargo Equal Weight → Overweight $575
Jun-09-23 11:30AM
Jun-08-23 04:13PM
08:30AM
Jun-06-23 07:18AM
06:29AM
05:30AM Loading…
05:30AM
Jun-05-23 08:55PM
Jun-04-23 10:59AM
09:28AM
Jun-03-23 11:52AM
08:00AM
07:45AM
Jun-01-23 10:04AM
08:30AM
May-31-23 09:37AM
05:06AM Loading…
05:06AM
May-25-23 10:14AM
10:07AM
May-24-23 09:00AM
May-23-23 09:55AM
May-22-23 05:43PM
May-17-23 08:45AM
May-16-23 07:54AM
May-15-23 08:50AM
May-13-23 08:00AM
May-11-23 01:25PM
May-10-23 06:30PM
08:07AM
May-04-23 12:40PM
May-03-23 07:00AM
04:00AM Loading…
04:00AM
May-02-23 07:00AM
05:14AM
Apr-29-23 08:58AM
Apr-28-23 03:33PM
12:11PM
11:24AM
09:56AM
09:28AM
Apr-27-23 05:25PM
04:27PM
04:03PM
10:23AM
06:00AM
Apr-26-23 08:00PM
08:00PM
10:52AM
Apr-25-23 10:20AM
Apr-24-23 06:35AM
Apr-20-23 08:10AM
Apr-19-23 09:40AM
Apr-17-23 04:53PM
12:23PM
09:45AM
08:00AM
Apr-13-23 04:28PM
09:45AM
07:25AM
Apr-08-23 09:45AM
Apr-06-23 07:45AM
05:30AM
03:59AM
Apr-05-23 09:08AM
09:00AM
Apr-02-23 03:16PM
Mar-31-23 06:15PM
08:45AM
Mar-29-23 07:45AM
Mar-25-23 05:41AM
Mar-24-23 12:10PM
11:59AM
06:59AM
Mar-23-23 09:53AM
Mar-21-23 06:15PM
06:00AM
Mar-20-23 09:00AM
02:15AM
Mar-18-23 06:29PM
Mar-16-23 11:14AM
Mar-15-23 06:15PM
Mar-13-23 07:30AM
Mar-09-23 06:15PM
09:53AM
08:00AM
Mar-08-23 10:19PM
Mar-07-23 04:59AM
Mar-06-23 04:04PM
10:05AM
Mar-03-23 06:15PM
02:38PM
08:20AM
Mar-02-23 04:04PM
05:05AM
Feb-28-23 04:56PM
05:52AM
05:00AM
Feb-24-23 09:45AM
09:37AM
Feb-23-23 09:00AM
Feb-22-23 04:04PM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pacelli Steven RobertEVP Managing Director Dexcom VMay 23Sale118.6541248,884132,274May 23 07:13 PM
Sylvain Jereme MEVP Chief Financial OfficerMay 22Sale117.582,400282,19274,711May 23 07:12 PM
Stern SadieEVP Chief Human Resources OffiMay 09Sale120.1939347,23582,859May 09 06:24 PM
Pacelli Steven RobertEVP Managing Director Dexcom VApr 27Sale126.005,031633,906132,686Apr 27 06:38 PM
Pacelli Steven RobertEVP Managing Director Dexcom VApr 24Sale124.6841251,368137,717Apr 26 04:36 PM
Leach Jacob StevenEVP Chief Technology OfficerApr 20Sale125.0030,7643,845,500259,613Apr 20 06:39 PM
Regan Barry J.EVP OperationsApr 20Sale124.502,214275,64368,258Apr 20 06:39 PM
Selvaraj Shelly RamasamySVP Chief Information OfficerApr 20Sale125.002,007250,87552,505Apr 20 06:39 PM
Flynn Paul REVP Global RevenueApr 17Sale120.002,781333,72052,112Apr 18 04:36 PM
Stern SadieEVP Chief Human Resources OffiApr 10Sale112.3539344,15483,252Apr 11 04:02 PM
SAYER KEVIN RPresident CEO and Chairman ofApr 03Sale114.4620,8122,382,069327,457Apr 05 04:56 PM
Brown Michael JonEVP Chief Legal OfficerApr 03Sale114.483,612413,49061,870Apr 05 04:56 PM
Pacelli Steven RobertEVP Managing Director Dexcom VMar 23Sale116.405,442633,449138,129Mar 27 05:08 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopMar 16Sale115.002,303264,84533,569Mar 17 04:14 PM
Stern SadieEVP Chief Human Resources OffiMar 14Sale111.8639343,96183,645Mar 15 04:03 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopMar 13Sale106.276,229661,95635,872Mar 14 04:46 PM
Flynn Paul REVP Global RevenueMar 13Sale106.272,782295,64354,893Mar 14 04:46 PM
Regan Barry J.EVP OperationsMar 13Sale106.272,010213,60370,472Mar 14 04:46 PM
Leach Jacob StevenEVP Chief Technology OfficerMar 06Sale114.7418,1442,081,822281,089Mar 06 08:05 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopMar 06Sale114.4022625,85426,536Mar 06 08:04 PM
SAYER KEVIN RPresident CEO and Chairman ofMar 01Sale109.9438,4644,228,611331,337Mar 02 05:16 PM
Pacelli Steven RobertEVP Managing Director Dexcom VFeb 23Sale111.6441245,996136,464Feb 23 06:34 PM
Sylvain Jereme MEVP Chief Financial OfficerFeb 22Sale114.542,400274,89664,837Feb 22 06:08 PM
SAYER KEVIN RPresident CEO and Chairman ofJan 30Sale106.1556,8446,034,123369,801Jan 31 04:07 PM
Regan Barry J.EVP OperationsJan 30Sale106.122,213234,84459,386Jan 31 04:07 PM
Pacelli Steven RobertEVP Managing Director Dexcom VJan 23Sale107.8641244,438136,876Jan 24 04:16 PM
SAYER KEVIN RPresident CEO and Chairman ofJan 20Sale105.7545,6074,822,872426,645Jan 24 04:17 PM
Pacelli Steven RobertEVP Managing Director Dexcom VDec 23Sale112.5741246,379137,288Dec 27 04:29 PM
Flynn Paul REVP Global RevenueDec 08Sale123.508,9881,110,01855,744Dec 08 06:07 PM
Sylvain Jereme MEVP Chief Financial OfficerNov 21Sale112.622,400270,28867,237Nov 22 06:25 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopSep 01Sale81.63540826,536Sep 06 09:33 AM
Pacelli Steven RobertEVP Managing Director Dexcom VAug 23Sale84.211,00084,210137,700Aug 24 05:25 PM
Pacelli Steven RobertEVP Managing Director Dexcom VJul 25Sale83.071,00083,070138,700Jul 25 06:00 PM
Pacelli Steven RobertEVP Managing Director Dexcom VJun 23Sale72.551,00072,550139,700Jun 27 04:46 PM